

PROGRAM

**EMN**

# 7<sup>th</sup> European Myeloma Network Meeting

**Prague**  
**April 16-18, 2026**

*Clarion Congress Hotel Prague*



## WELCOME MESSAGE

Dear Colleagues and friends,

Get ready for an incredible event in one of Europe's most beautiful cities! As previously announced, Prague will host the European Myeloma Network meeting EMN2026 on April 16-18, 2026. Following the great success of our annual meetings over the years, we are thrilled to bring our community together once again and invite you to an enriching and collaborative experience.

Prague is a truly inspiring backdrop for our meeting. Our venue, the Clarion Conference Center, is ideally located.

The EMN 2026 program is designed to address the most critical questions in multiple myeloma today. We will focus on current diagnostic and clinical challenges, cutting-edge biology, novel treatments, practical guidelines, with a careful look at future directions and innovations. We anticipate lively discussions on topics such as:

- Novel treatments and their sequencing in newly diagnosed (NDMM) and relapsed/refractory (RRMM) disease
- Minimal Residual Disease (MRD) and its role in evaluating treatment efficacy
- The future of myeloma research, including the role of AI in trial design and the clinical and economic implications of new therapies
- Best approach for High-Risk patients
- Lively debates with experts in the field coming from all over Europe and beyond

We believe that our strength lies in our collaboration. We are proud to continue our work with patient associations, national groups, and scientific societies like the European Hematology Association - EHA. We are also grateful for the collaboration with industry partners who contribute to our innovative clinical trials and help shape this outstanding scientific program.

Your participation in the various discussion sessions will be key to making EMN2026 a dynamic and highly formative event.

We are confident that EMN2026 will be an unforgettable experience, offering a unique blend of high-level science and the rich cultural heritage of Prague.

We look forward to welcoming you!

Roman Hajek & Jakub Radocha  
EMN2026 Local Organizers

On behalf of the EMN Scientific Program Coordinators

## FACULTY

Meral	Beksac	Ankara, Turkey	Maximilian	Merz	New York, Usa
Hedwig	Blommestein	Rotterdam, The Netherlands	Jana	Mihalyova	Ostrava, Czech Republic
Mario	Boccardo	Torino, Italy	Jiří	Minařík	Brno, Czech Republic
Niccolo'	Bolli	Milano, Italy	Monique C.	Minnema	Utrecht, The Netherlands
Guldane	Cengiz-Seval	Ankara, Turkey	Adrian	Mosquera Orgueira	Santiago De Compostela, Spain
Ajai	Chari	San Francisco, Usa	Enrique Maria	Ocio San Miguel	Santander, Span
Heather	Cooper Ortner	Los Angeles, Usa	Rakesh	Popat	London, United Kingdom
Michel	Delforge	Leuven, Belgium	Noemi	Puig	Salamanca, Spain
Meletios-Athanasios	Dimopoulos	Athens, Greece	Marc	Raab	Heidelberg, Germany
Dominik	Dytfeld	Poznan, Poland	Jakub	Radocha	Hradec Kralove, Czech Republic
Hermann	Einsele	Würzburg, Germany	Leo	Rasche	Würzburg, Germany
Maria	Gavriatopoulou	Athens, Greece	Angela	Reidel	Würzburg, Germany
Francesca Maria	Gay	Torino, Italy	Anaïs	Schavgoulidze	Toulouse, France
Roman	Hajek	Ostrava, Czech Republic	Fredrik Hellem	Schjesvold	Oslo, Norway
Doris	Hansen	Tampa, Usa	Fernando	Serra Leal Da Costa	Lisboa, Portugal
Michael	Hudecek	Würzburg, Germany	Tereza	Ševčíková	Ostrava, Czech Republic
Tomas	Jelinek	Ostrava, Czech Republic	Febe	Smits	Amsterdam, The Netherlands
Cristina	Joao	Lisboa, Portugal	Pieter	Sonneveld	Rotterdam, The Netherlands
Nisha	Joseph	Atlanta, Usa	Claudia	Stege	Amsterdam, The Netherlands
Martin	Kaiser	Oxford, United Kingdom	Tomas	Stopka	Prague, Czech Republic
Efstathios	Kastritis	Athens, Greece	Evangelos	Terpos	Athens, Greece
Maria	Krauth	Vienna, Austria	Maria	Themeli	Amsterdam, The Netherlands
Shaji	Kumar	Rochester, Usa	Cyrille	Touzeau	Nantes, France
Ola	Landgren	Miami, Usa	Niels	Van De Donk	Amsterdam, The Netherlands
Xavier	Leleu	Poitiers Cedex, France	Niels	Weinhold	Heidelberg, Germany
Barbara	Leonardi	Brussels, Belgium	Elena	Zamagni	Bologna, Italy
Elias K.	Mai	Heidelberg, Germany	Sonja	Zweegman	Amsterdam, The Netherlands
Maria Victoria	Mateos	Salamanca, Spain			

## TIMETABLE

Thursday, April 16, 2026	Friday, April 17, 2026	Saturday, April 18, 2026
	09.00 - 10.00 <b>SESSION V</b> DEBATE - OPTIMAZING POSITION OF T-CELL IMMUNOTHERAPY	09.00 - 09.45 <b>SESSION X</b> DEBATE - HIGH-RISK SMM: TO TREAT OR NOT TO TREAT?
10.00 - 10.15 <b>OPENING CEREMONY</b>	10.00 - 10.30 <b>SESSION VI</b> PATIENTS ASSOCIATIONS	09.45 - 10.45 <b>SESSION XI</b> HOT TOPICS RELEVANT FOR THE MANAGEMENT OF MYELOMA PATIENTS
10.15 - 11.25 <b>SESSION I</b> GENOMIC AND MONOCLONAL GAMMOPATHIES	10.30 - 11.00 <b>COFFEE BREAK AND POSTER VIEWING</b>	10.45 - 11.15 <b>COFFEE BREAK AND POSTER VIEWING</b>
11.25 - 12.25 <b>SESSION II</b> TRASLATIONAL RESEARCH SESSION	11.00 - 12.30 <b>SESSION VII</b> RELAPSED/REFRACTORY MULTIPLE MYELOMA	11.15 - 12.15 <b>SESSION XII</b> EHA - EMN JOINT SESSION: FROM GUIDELINES TO REAL LIFE
12.25 - 13.30 <b>LUNCH AND MEET THE EXPERT SESSIONS</b>	12.30 - 14.00 <b>LUNCH AND MEET THE EXPERT SESSIONS</b>	12.15 - 13.25 <b>SESSION XIII</b> REAL WORLD EVIDENCE
13.30 - 15.00 <b>BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM</b> Improving outcomes in multiple myeloma: latest evidence and future perspectives	14.00 - 15.30 <b>JOHNSON AND JOHNSON SPONSORED SYMPOSIUM</b> The red thread of survival: evolving strategies to enhance outcomes in multiple myeloma	13.25 - 13.30 <b>CONCLUSIONS AND FINAL GREETINGS</b>
15.00 - 16.10 <b>SESSION III</b> NEWLY DIAGNOSED MULTIPLE MYELOMA	15.30 - 16.30 <b>SESSION VIII</b> PREDICTIVE MODELING: RESHAPING CLINICAL TRIALS AND ECONOMIC EVALUATIONS	
16.10 - 16.40 <b>COFFEE BREAK AND POSTER VIEWING</b>	16.30 - 17.00 <b>COFFEE BREAK AND POSTER VIEWING</b>	
16.40 - 18.10 <b>GSK SPONSORED SYMPOSIUM</b> Use of BCMA agents in early relapse and frontline	17.00 - 17.30 <b>ONCOPEPTIDES SPONSORED LECTURE</b> Bridging the gap: translating EHA-EMN guidelines into real-world melfalan flufenamide use	
18.10 - 19.10 <b>SESSION IV</b> UNMET MEDICAL NEEDS	17.30 - 18.45 <b>SESSION IX</b> EMN CORE TEAM: FUTURE INNOVATIONS IN MULTIPLE MYELOMA	
19.20 - 20.15 <b>WELCOME COCKTAIL</b>		

## CONGRESS INFORMATION

### VENUE

Clarion Congress Hotel Prague  
Freyova 945/33,  
190 00 Praha 9-Vysočany, Czechia  
Ph +420 211 131 139  
www.clarioncongresshotelprague.com

### HOW TO REACH THE MEETING VENUE

The hotel can be found directly at Vysočanská metro station (line B), which takes you to the centre of Prague in 10 minutes.

### FROM PRAGUE AIRPORT

#### By taxi:

The journey from Václav Havel Airport takes 30 - 45 minutes by taxi (19.5 km).

#### By public transport:

The journey takes about 50 minutes.  
From Terminal 1 and 2 – Trolleybus nr. 59 to 'Nadrazi Veleslavin' station → metro A line (green) to 'Mustek'  
→ transfer to metro B line to 'Vysocanska'

### FROM TRAIN STATION

#### By taxi:

It takes about 15 minutes by taxi to reach the hotel from the Central Train Station or Florenc Bus Station.

#### By public transport:

Metro C from 'Hlavni nadrazi' station line to 'Florenc' → transfer to metro B line to 'Vysocanska' or you may take another train with stop at 'Praha – Vysocany' train station and then 10 mins by walk directly to hotel.

### BY CAR

D1 motorway (from Brno or Vienna): take the D1 motorway towards "Centrum", turn right in the direction of Karlín and Vysočany, drive for roughly 5 km. Turn right into Českomoravská Street in the direction of the O2 Arena. Drive for roughly 1 km and turn left into Freyova Street. After about 600 metres you will see the Clarion Congress Hotel Prague\*\*\*\* on your left.

E55 from North: Take the E 55 and when you arrive in Prague turn right at the intersection with Kolbenova Street and continue towards the centre. After about 1 kilometre you will see the Clarion Congress Hotel Prague\*\*\*\*.

### PARKING

Parking available at the congress venue. It is possible to park only on the P2 floor with a special congress rate. The driveway is marked by light panels.  
Parking on P1 floor has different rates because it is dedicated to visitors of Shopping Mall Fenix.

## REGISTRATION FEES

Registration Categories	Online Registration	Onsite Registration
Standard	€ 500,00	€ 550,00
Participants under 35 years	€ 250,00	€ 300,00
Nurse and Data Managers	€ 200,00	€ 250,00
Exhibitors*	€ 200,00	€ 250,00

To avoid long lines at the on-site registration counters, we encourage you to register for the meeting in advance.

The registration fee includes:

- Participation in the scientific sessions
- Access to the exhibition and poster areas
- Conference kit
- Certificate of attendance
- Lunches
- Coffee breaks
- Welcome cocktail

\* Exhibitor fee DOES NOT include: conference kit, participation in the scientific sessions.

## REGISTRATION HOURS

Individuals and Exhibitors	
Wednesday, April 15, 2026	16.00 – 18.30
Thursday, April 16, 2026	07.30 – 18.00
Friday, April 17, 2026	08.00 – 18.00
Saturday, April 18, 2026	08.00 – 10.00
Groups	
Wednesday, April 18, 2026	16.00 – 18.30

## REGISTRATIONS BADGES

Badges and meeting materials will be given at the counters in the registration area.

Remember to print prior and to bring with you the invitation letter and the badge QRcode you received in the “Registration Info” automatic e-mail.

All registered participants, speakers, sponsors and exhibitors will be given a badge which must be worn in order to be admitted to the scientific sessions.

Badge is mandatory to enter the congress area.

A self-printing system will be available in the Registration Area. Delegates, sponsors and exhibitors will be able to collect their badges simply by having their personal QR Code scanned by the optical reader at the self-printing machines.

Speakers are kindly requested to collect their badges at the Registration desk.

The QRcode on the badge stores the following personal information: name, surname, country and email address provided at the time of registration. It can be used by exhibitors to register visitors to their booths and to send additional information on their products and services.

## CERTIFICATE OF ATTENDANCE

Delegates and speakers will be able to collect the certificate of attendance by having their personal QRcode read at the self-printing machines.

## CATERING

Lunches, coffee breaks and the welcome cocktail are included in the registration fee.

You will be admitted showing your badges.

The EMN Welcome Cocktail is scheduled on Thursday, April 16, 2026 from 19.20 to 20.15 in the exhibition area.

## EXHIBITION AREA

The exhibition area will be open at the following hours:

Thursday, April 16, 2026	09.00 – 19:00
Friday, April 17, 2026	09.00 – 18:00
Saturday, April 18, 2026	09.00 – 12:00

## AUDIO - VIDEO RECORDING

Audio-video recording is prohibited.

Only authorized staff can provide audio-video recording services

## OFFICIAL WEBSITE

[www.emn2026.com](http://www.emn2026.com)

## APP

A special mobile app has been developed for this congress.

Use the app to find sessions of interest, create your own program, find and read all the abstracts.

Download the “EMN2026” app from Apple App store or Google Play.

## SCIENTIFIC INFORMATION

### LANGUAGE

The meeting will be in English with no simultaneous translation into other languages.

### EBAH CME CREDITS

The program of the “7th European Myeloma Network Meeting” has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. **13 CME credits** for Physicians, Biologists, Medical Laboratory Scientists, Nurses and Chemists. EBAH Credit Points will be awarded for the Plenary Sessions.

To request credits, please fill out the form and return it to the registration desk at the end of the meeting.

We remind you that it is necessary to have an EBAH-CME account in order to claim for credits.

Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

### SLIDE CENTER

Thursday April 16, 2026	08.00 – 19.00
Friday April 17, 2026	08.00 – 18.00
Saturday April 18, 2026	08.00 – 11.00

### POSTER AREA

Posters will be on display in the Poster Area for three days.

Posters should be installed/removed during the indicated set-up time:

Installation	Thursday, April 16, 2026	09.00 – 11.00
Tear off	Saturday, April 18, 2026	12.00 – 13.00

Materials to hang posters with will be available at the poster area. The Congress provides one board for each poster, the author is responsible for hanging and for removing the poster. Please note that the organisers do not take any responsibility for returning uncollected material to the authors.

### MEET THE EXPERT SESSIONS

Meet the Expert Sessions take place on April 16 and April 17, 2026 during the lunch break.

Registration is free of charge but spots are limited. Preregistration to attend these sessions is necessary. If spots are still available, you can also register onsite during registration hours.

We suggest that you do this early in order to secure your spot.

ROOM	THURSDAY, APRIL 16, 2026	FRIDAY, APRIL 17, 2026
VIRGO	<b>1.</b> How I handle the five senses - minimizing quality of life impact of novel therapies	<b>4.</b> How do I manage infections during antiBCMA therapy?
LEO	<b>2.</b> How do I bridge patients to CAR-T?	<b>5.</b> How do I sequence immune therapies?
TAURUS	<b>3.</b> Going with the flow - MRD in clinical routine	

### CHANGES

Parts of the program may be changed without prior notice.

## PROGRAM

## THURSDAY, APRIL 16, 2026

10.00-10.15 **OPENING CEREMONY** MERIDIAN

10.15-11.25 **SESSION I:  
GENOMIC AND MONOCLONAL GAMMOPATHIES** MERIDIAN 

*Chairpersons: T. Ševčíková, N. Weinhold*

- Optimal NGS panel for MM – **N. Bolli**
- New genomic definition of high-risk MM and applicability – **A. Schavgoulidze**
- Is there a chance to improve definition of high-risk SMM with genomic tools? – **N. Weinhold**
- Oral Communication

### B01

TIME-RESOLVED MULTI-LAYERED PROFILING IDENTIFIES RESOLUTION OF RIBOSOME COLLISIONS AND TRANSLATIONAL RECOVERY AS MECHANISMS CONTRIBUTING TO PROTEASOME INHIBITOR RESISTANCE

*J. Zhou, N.T. Crump, M. Román-Trufero, H.W. Auner (London-UK, Lausanne-CH)*

### B02

THE PROGNOSTIC IMPACT OF BONE MARROW PLASMA CELL INFILTRATION AT DIAGNOSIS IN AL AMYLOIDOSIS

*K. Aslantaş, Ş. Özlü, I. Kuzu, M. Beksaç, G. Cengiz Seval (Ankara-TR)*

- Panel discussion

11.25-12.25 **SESSION II:  
TRANSLATIONAL RESEARCH SESSION** MERIDIAN 

*Chairpersons: T. Cupedo, M. D'Agostino*

- Genomics of EMD – **A. Reidel**
- T and NK cells in the extramedullary myeloma tumor microenvironment – **T. Jelinek**
- Oral Communication

### B03

TRANSCRIPTOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN MULTIPLE MYELOMA (MM) REVEALS EGRESSION-ASSOCIATED PROFILE RELATED TO CTC BURDEN

*D. Bilek, E. Radova, V. Kapustova, M. Warmuzova, O. Venglar, S. Nenarokov, L. Broskevicova, J. Vrana, M. Kudelkova, L. Muronova, T. Popkova, J. Mihalyova, H. Plonkova, M. Durante, B. Diamond, M. Simicek, J. Bago, D. Zihala, T. Sevcikova, O. Landgren, R. Hajek, T. Jelinek (Ostrava-CZ, Miami-USA)*

- Panel Discussion

12.25-13.30 **Lunch and simultaneous meet the expert sessions on:**

1. How I handle the five senses - minimizing quality of life impact of novel therapies – **M. Delforge, C. Stege** VIRGO
2. How do I bridge patients to CAR-T? – **J. Mihalyova, L. Rasche** LEO
3. Going with the flow - MRD in clinical routine – **T. Jelinek, N. Puig** TAURUS

13.30-15.00 **BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM** MERIDIAN  
**Improving outcomes in multiple myeloma:  
latest evidence and future perspectives**

*Chairperson: R. Hájek*

- Welcome and introduction - **R. Hájek**
- How can myeloma biology inform novel approaches? – **C. Pawlyn**
- Looking beyond today's frontline treatment strategies – **N. van de Donk**
- Opening a new chapter in early RRMM - **TBD**
- Panel discussion, Q&A and closing remarks

15.00-16.10 **SESSION III:  
NEWLY DIAGNOSED MULTIPLE MYELOMA** MERIDIAN 

*Chairpersons: M. Raab, T. Stopka*

- Treatment beyond MRD negativity - whom and how long? – **X. Leleu**
- Novel maintenance strategies – **N. van de Donk**
- Functional imaging as MRD marker – **E. Zamagni**
- Is it really necessary to treat all eligible elderly with quadruplet? – **S. Zweegman**
- Oral Communication

### B04

BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM

*L. Bertamini, D. Zihala, I.V. Kostopoulos, M. D'Agostino, E. Martín-Sánchez, J.J. Garcés Latre, D. Hofste Op Bruinink, N. Puig, S. Zweegman, G. Bertuglia, P. Malandrakis, T. Sevcikova, T. Cupedo, N.W.C.J. van de Donk, M.T. Cedena, P. Musto, I. Ntanasis-Stathopoulos, O. Venglar, M. Van Duin, J.J. Lahuerta, D. Rota Scalabrini, O. Tsitsilonis, T. Popkova, J. Blade, E. Zamagni, M. Gavriatopoulou, L. Muronova, B. Van Der Holt, P. Moreau, M.V. Mateos, M. Galli, E. Katodritou, M. Stork, A. Belotti, P. Rousakis, M. Borsky, J. Corre, M. Boccadoro, M. Dimopoulos, R. Hajek, J. San Miguel, P. Sonneveld, F. Gay, E. Terpos, A. Broijl, B. Paiva, T. Jelinek (Rotterdam-NL, Ostrava-CZ, Athens-GR, Torino-IT, Pamplona-ES, Salamanca-ES, Amsterdam-NL, Madrid-ES, Bari-IT, Barcelona-ES, Bologna-IT, Nantes-FR, Bergamo-IT, Thessaloniki-GR, Brno-CZ, Brescia-IT, Toulouse-FR)*

- Panel Discussion

16.10-16.40 Coffee break and poster viewing

EXHIBITION AREA

16.40-18.10 **GSK SPONSORED SYMPOSIUM**

**Use of BCMA agents in early relapse and frontline**

Chairperson: **K. Ramasamy**

- A new target to treat early relapse myeloma - **E. Mai**
- Different BCMA options and deep dive on data - **F. Schjesvold**
- Clinical use of BCMA options, pros and cons - **K. Ramasamy**
- Right patient for the right BCMA treatment - **R. Hájek**
- Panel discussion

MERIDIAN

18.10-19.10 **SESSION IV:**

**UNMET MEDICAL NEEDS**

Chairpersons: **C. Joao, M. Krauth**

- How do I treat patients with EMD? - **M. Beksac**
- How do I treat patients with HR MM? - **M. Kaiser**
- How do I treat patients with suboptimal response? - **F. Schjesvold**
- Oral Communication

**B05**

SPATIAL IMAGING UNLOCKS THE POTENTIAL OF CHARTING MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE

V. Desantis, A. Andriano, G. De Martino, T. Düking, O. Hartwig, G. Ingravallo, M. Biondo, C. Botta, R. Ria, A. Vacca, A.G. Solimando (Bari-IT, Bergisch Gladbach-DE, Catania-IT, Palermo-IT)

- Panel Discussion

MERIDIAN



19.20-20.15 Welcome cocktail

## FRIDAY, APRIL 17, 2026

09.00-10.00

**SESSION V:  
DEBATE - OPTIMIZING POSITION OF T-CELL  
IMMUNOTHERAPY**

Chairpersons: **A. Chari, T. Jelinek**

- Upfront in all eligible NDMM patients - **C. Touzeau**
- In patients with no sustained MRD neg post induction - **F. Gay**
- Vote and discussion
- Oral Communication

**B06**

BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE/DEXAMETHASONE IN NEWLY DIAGNOSED INTERMEDIATE-FIT AND FRAIL MULTIPLE MYELOMA: LONG-TERM EFFICACY AND SAFETY FROM THE PHASE 1/2 BELARD CLINICAL TRIAL

E. Terpos, M. Gavriatopoulou, I.N. Stathopoulos, P. Malandrakis, N. Kanellias, M. Migkou, F. Theodorakakou, E. Solia, E.E. Papaïakovou, E. Kastritis, M.A. Dimopoulos (Athens-GR, Seoul-KOR)

MERIDIAN



10.00-10.30

**SESSION VI:  
PATIENTS ASSOCIATIONS**

Chairpersons: **M. Boccadoro, F. Serra Leal da Costa**

- MPE - **B. Leonardi**
- IMF - **H. Cooper Ortner**
- Panel Discussion

MERIDIAN



10.30-11.00

Coffee break and poster viewing

EXHIBITION AREA

- 11.00-12.30 **SESSION VII:  
RELAPSED/REFRACTORY MULTIPLE MYELOMA** MERIDIAN  
  
*Chairpersons: J. Minarik, E.M. Ocio San Miguel*
- CelMods in the treatment algorithm – **N. Joseph**
  - Immunotherapy beyond BCMA - incorporating novel targets – **R. Popat**
  - Resistance to immunotherapy – **L. Rasche**
  - Novel small molecules – **E.M. Ocio San Miguel**
  - Oral Communication
- B07**  
PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES  
M. Talarico, A. Cattabriga, L. Pagnini, V. Solli, S. Barbato, S. Ghibellini, S. Masci, E. Manzato, M. Puppi, M. Iezza, K. Mancuso, L. Pantani, P. Tacchetti, C. Terragna, M. Ursi, E. Maffini, F. Bonifazi, S. Brocchi, C. Mosconi, C. Nanni, S. Fanti, E. Zamagni (Bologna-IT)
- Panel Discussion
- 12.30-14.00 **Lunch and simultaneous meet the expert sessions on:**
4. How do I manage infections during antiBCMA therapy?  
**J. Radocha, F. Smits** VIRGO
  5. How do I sequence immune therapies?  
**F. Serra Leal Da Costa, M.C. Minnema** LEO
- 14.00-15.30 **JOHNSON AND JOHNSON SPONSORED SYMPOSIUM** MERIDIAN  
**The red thread of survival: evolving strategies to enhance outcomes in multiple myeloma**  
*Chairperson: M. Delforge*
- Welcome and introduction – **M. Delforge**
  - From MRD to managing real decisions: weaving in technology to decision-making in NDMM – **TBD**
  - Panel discussion: perspectives on treatment goals in NDMM
  - Durable remission at first relapse: tailoring 2L treatment – **E. Zamagni**
  - From clinical trials to real-world data: stitching together the evidence in TCE RRMM – **R. Popat**
  - Panel discussion: Perspectives on treatment goals in RRMM
  - Closing remarks – **M. Delforge**

- 15.30-16.30 **SESSION VIII:  
PREDICTIVE MODELING: RESHAPING CLINICAL TRIALS AND ECONOMIC EVALUATIONS** MERIDIAN  
  
*Chairpersons: R. Hájek, F. Schjesvold*
- Accelerating clinical development with predictive models: lessons from the Perseus and Cepheus trials – **P. Sonneveld**
  - MRD negativity as a surrogate endpoint: a new paradigm for trial success – **O. Landgren**
  - Economic impact of deep and durable remissions – **H. Blommestein**
  - Panel Discussion
- 16.30-17.00 **Coffee break and poster viewing** EXHIBITION AREA
- 17.00-17.30 **SPONSORED LECTURE ONCOPEPTIDES** MERIDIAN  
**Bridging the gap: translating EHA-EMN guidelines into real-world melfalan flufenamide use**  
**M. Raab, E. Zamagni**
- 17.30-18.45 **SESSION IX:  
EMN CORE TEAM: FUTURE INNOVATIONS IN MULTIPLE MYELOMA** MERIDIAN  
  
*Chairpersons: J. Radocha, L. Rasche*
- AI algorithms for decision-making – **A. Mosquera**
  - Novel CAR-T constructs? – **M. Themeli**
  - What can we do with the cells in the fridge? – **G. Cengiz-Seval**
  - Oral Communication
- B08**  
LONGITUDINAL IMMUNE MONITORING WITH A STANDARDIZED 8-COLOR FLOW CYTOMETRY PANEL REVEALS DISTINCT KINETICS AND PERSISTENCE IN PATIENTS TREATED WITH CILTA-CEL VS AXI-CEL  
O. Venglar, V. Hrabcakova, O. Soucek, K. Kutejova, D. Zihala, J. Mihalyova, M. Hornakova, T. Sevcikova, L. Broskevicova, L. Janska Vojtkova, M. Borsky, J. Radocha, P. Zak, M. Doubek, T. Kalina, R. Hajek, D. Belada, F. Folber, T. Jelinek (Ostrava-CZ, Brno-CZ, Hradec Kralove-CZ, Prague-CZ, Miami-USA)
- Panel Discussion

**SATURDAY, APRIL 18, 2026**

09.00-09.45 **SESSION X** MERIDIAN   
**DEBATE - HIGH-RISK SMM: TO TREAT OR NOT TO TREAT?**

Chairpersons: D. Dytfeld, M. Gavriatopoulou

- YES to treatment – M.V. Mateos
- NO to treatment – M. Boccadoro
- Vote and discussion
- Oral Communication

**B09**

DARATUMUMAB MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: AQUILA OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE

F. Schjesvold, P.M. Voorhees, M.A. Dimopoulos, Y.C. Cohen, V. Hungria, I. Sandhu, J. Lindsay, R.I. Baker, K. Suzuki, H. Kosugi, M.D. Levin, M. Beksac, K. Stockerl-Goldstein, H. Magen, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, A.K. Mylin, S. Hallam, S. Bringham, K. Uttervall, B. Pula, A.M. Khan, E. Medvedova, J.C. Ye, A.J. Cowan, P. Moreau, M.V. Mateos, H. Goldschmidt, D. Vieyra, A. Raval, L. Sha, L. Li, E. Rousseau, R.M. Dennis, R.L. Carson, S.V. Rajkumar (Oslo-NO, Charlotte-USA, Athens-GR, Tel Aviv-IL, São Paulo-BRA, Edmonton-CAN, Canterbury-UK, Perth-AUS, Tokyo-JAP, Ogaki-JAP, Dordrecht-NL, Ankara-TR, St. Louis-USA, Badalona-ES, Budapest-HU, Buenos Aires-ARG, Hasselt-BE, Prague-CZ, Copenhagen-DK, London-UK, Turin-IT, Stockholm-SE, Warsaw-PL, Columbus-USA, Portland-USA, Houston-USA, Seattle-USA, Nantes-FR, Salamanca-ES, Heidelberg-DE, Spring House-USA, Raritan-USA, Shanghai-CHN, Beerse-BE, Wayne-USA, Rochester-USA)

09.45-10.45 **SESSION XI** MERIDIAN   
**HOT TOPICS RELEVANT FOR THE MANAGEMENT OF MYELOMA PATIENTS**

Chairpersons: E. Dimopoulos, P. Sonneveld

- How to select CAR-T or bispecifics in 2nd line? – H. Einsele
- Response assessment - new criteria and tools – S. Kumar
- Treatment of patients with renal failure including dialysis in the era of immunotherapies – E. Kastritis
- Panel Discussion

10.45-11.15 **Coffee break and poster viewing**

EXHIBITION AREA

11.15-12.15 **SESSION XII** MERIDIAN   
**EHA-EMN JOINT SESSION: FROM GUIDELINES TO REAL LIFE**

Chairpersons: P. Sonneveld, E. Terpos

- Introduction – E. Terpos
- From guidelines to real life: optimal work-up and staging to guide treatment algorithms – E. Zamagni
- From guidelines to real life: the patient journey from 2026 onwards – E. Terpos
- Panel Discussion
- Closing – P. Sonneveld

12.15-13.25 **SESSION XIII** MERIDIAN   
**REAL WORLD EVIDENCE**

Chairpersons: R. Hájek, E. Mai

- Generating real world data - platforms and future possibilities – D. Hansen
- Harmony – E. Mai
- Real world evidence in bispecifics and CAR-T – M. Merz
- Honeur – M. Delforge
- Oral Communication

**B10**

HEPTA-REFRACTORY MULTIPLE MYELOMA: BIOLOGY, PROGNOSIS, AND TREATMENT  
C. Riedhammer, M. Truger, H. Lee, L.B. Leyboldt, M. Meggendorfer, S. Hutter, H. Müller, J. Mersi, S.K. Kadel, T. Buchwald, R. Kosch, M. Helal, N. Afrin, A. Rosenwald, E. Gerhard-Hartmann, A. Brioli, J. Krönke, T. Haferlach, C. Haferlach, K.C. Weisel, P. Neri, H. Einsele, K.M. Kortüm, J.M. Waldschmidt, N. Bahlis, N. Weinhold, L. Rasche (Würzburg-DE, Munich-DE, Calgary-CAN, Hamburg-DE, Greifswald-DE, Hannover-DE, Heidelberg-DE)

- Panel Discussion

13.25-13.30 **CONCLUSIONS AND FINAL GREETINGS** MERIDIAN

**POSTER**

## POSTER

### 1. BIOLOGY AND PRECLINICAL

#### P01

CIRCULATING TUMOR CELLS (CTCS) IMPROVE RISK STRATIFICATION ACCORDING TO THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) AND THE IMS-IMWG CONSENSUS GENOMIC STAGING (CGS) IN NDMM PATIENTS. AN ANALYSIS FROM THE EUROPEAN CTC CONSORTIUM

M. D'agostino, E. Martín-Sánchez, D. Žihala, I. Kostopoulos, J.J. Garcés, N. Puig<sup>7</sup>, G. Bertuglia, T. Ševčíková, T. Cupedo, M. Van Duin, J. Keats, E. Zamagni, P. Moreau, S. Zweegman, B. Van Der Holt, D. Hofste Op Bruinink, E. Dama, J. Corre, M. Boccadoro, M.A. Dimopoulos, R. Hájek, B. Paiva, P. Sonneveld, A. Broijl, E. Terpos, T. Jelínek, J. San-Miguel, F. Gay, L. Bertamini (*Torino-IT, Pamplona-ES, Ostrava-CZ, Athen-GR, New York-USA, Salamanca-ES, Rotterdam-NL, Phoenix-USA, Bologna-IT, Nantes-FR, Amsterdam-NL, EMN-IT, Toulouse-FR, Seoul-KR, EMN-NL*)

#### P02

INTERACTION BETWEEN MYELOMA AND BONE MARROW MESENCHYMAL STEM CELLS

H. Ahmed, J. Vorwerk, M. Hussein, P.K. Patnana, A.K. Rout, U. Guenther, N.V. Bubnoff, W. Mansour, C. Khandanpour (*Oldenburg-DE, Lübeck-DE, Hamburg-DE*)

#### P03

BONE MARROW MICROENVIRONMENT-DEPENDENT INDUCTION OF MTORC1 CAUSES THERAPY RESISTANCE IN MULTIPLE MYELOMA

M.H. Janssens, G.D. Wilde, M. Spaargaren, R.W. Groen, J.E.J. Guikema (*Amsterdam-NL*)

#### P04

DEVELOPMENT OF A NEW 3D EX VIVO MODEL FOR MULTIPLE MYELOMA

M. Domingos, E. Carneiro, A. Queirós, C. João (*Lisbon-PT*)

#### P05

ZEBULARINE MODULATES DNA METHYLTRANSFERASE EXPRESSION THROUGH ASSOCIATED HISTONE COMPLEXES AT THEIR PROMOTERS IN MULTIPLE MYELOMA CELL LINES

L. Slavickova, D. Svehlova, J. Minarik, K. Smesny Trkova (*Olomouc-CZ, Ostrava-CZ*)

#### P06

FROM BENCH TO BEDSIDE: DRUG SENSITIVITY PROFILING TO OPTIMIZE THERAPY IN RELAPSED MULTIPLE MYELOMA

R. Cassano Cassano, T. Martins, D. Coffey, G. Buda, S. Galimberti, L.M.A. Melillo, R. Donnelly, M. Kwok, D. Green, R. Banerjee, K. Cicero, T. Gooley, R. Silbermann, P. Becker, A.J. Cowan, D. Dima (*Seattle-USA, Foggia-IT, Miami-USA, Pisa-IT, Portland-USA*)

#### P07

CYTOKINE AND BONE MICROENVIRONMENT PROFILES REFLECT DISEASE STAGE AND OSTEOLYTIC INVOLVEMENT IN MULTIPLE MYELOMA

J. Minarik, J. Proskova, V. Latal, P. Krhovska, T. Pika (*Olomouc-CZ*)

#### P08

MODULATION OF MIR-29B EXPRESSION AND APOPTOSIS IN MULTIPLE MYELOMA CELL LINES FOLLOWING TREATMENT WITH HALF-SANDWICH OS(II) COMPLEXES

D. Švehlová, L. Ševčíková, I. Frydrych, P. Štarha, K.S. Trtková (*Olomouc-CZ, Ostrava-CZ*)

#### P09

CYTOGENOMIC AND SEQUENCING ANALYSIS IN MULTIPLE MYELOMA PATIENTS WITH CIRCULATING PLASMA CELLS

J. Balcarkova, A. Navratilova, J. Navratilova, M. Novak, V. Latal, T. Pika, P. Krhovska, H. Urbankova, T. Papajik, J. Minarik (*Olomouc-CZ*)

### 2. NEWLY DIAGNOSED MULTIPLE MYELOMA

#### P10

HIGH ACCURACY OF NEXT-GENERATION FLOW (NGF) IN PREDICTING MEASURABLE RESIDUAL DISEASE BY NEXT-GENERATION SEQUENCING (NGS) IN THE 10\_RANGE: A PROSPECTIVE COMPARISON WITHIN THE PHASE III EMN24 ISKIA TRIAL

M. D'agostino, M. Van Duin, W. Roeloffzen, M.A. Dimopoulos, L. Rosiñol, M. Van Der Klift, J. Martínez-López, A. Oriol, E. Katodritou, K.L. Wu, P. Rodríguez Otero, R. Hájek, E. Dama, D. Oddolo, G. Gazzera, E.M. Van Leeuwen-Segarceanu, N.W.C.J. Van De Donk, S. De Jonge-Peeters, T.S. Slørdahl, J. Straub, M. Westerman, F. Schjesvold, J. Bladé, H. Einsele, M. Boccadoro, P. Sonneveld, A. Broijl, F. Gay (*Torino-IT, Rotterdam-NL, Groningen-NL, Athens-GR, Seoul-KR, Barcelona-ES, Breda-NL, Madrid-ES, Thessaloniki-GR, Antwerp-BE, Pamplona, Navarra-ES, Ostrava-CZ, EMN-IT, Nieuwegein-NL, Amsterdam-NL, Nijmegen-NL, Trondheim-NO, Prague-CZ, Alkmaar-NL, Oslo-NO, Würzburg-DE, EMN-NL*)

#### P11

PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL

J.X. Jin, V.R. Ginde, S. Huhn, P. Reichert, U. Bertsch, R. Fenk, B. Besemer, A. Boquoi, R. Schroers, I.V. Metzler, M. Hänel, C. Mann, L.B. Leypoldt, B. Heilmeier, C. Scheid, T. Peters-Regehr, I.W. Blau, C. Müller-Tidow, S. Luntz, T.A.W. Holderried, K. Trautmann-Grill, D. Gezer, M. Klaiber-Hakimi, M. Müller, E. Shumilov, W. Knauf, C.S. Michel, T. Geer, H. Riesenberger, C. Lutz, M.S. Raab, N. Weinhold, M. Hoffmann, A. Benner, P. Findeisen, K.C. Weisel, H.J. Salwender, H. Goldschmidt, E.K. Mai (*Heidelberg-DE, Düsseldorf-DE, Tübingen-DE, Essen-DE, Bochum-DE, Frankfurt am Main DE, Chemnitz-DE, Marburg-DE, Hamburg-DE, Regensburg-DE, Cologne-DE, Schwetzingen-DE, Berlin-DE, Bonn-DE, Dresden-DE, Aachen-DE, Hannover-DE, Münster-DE, Mainz-DE, Schwäbisch-Hall-DE, Bielefeld-DE, Koblenz-DE, Ludwigshafen-DE*)

**P12**

SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE (VRD) WITH DARA + LENALIDOMIDE (DR) MAINTENANCE IN TRANSPLANT-ELIGIBLE (TE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGAT

P. Sonneveld, P. Moreau, H. Einsele, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, H. Pei, A. Sitthi-Amorn, R.L. Carson, P. Rodríguez-Otero, M.A. Dimopoulos, M. Boccadoro (*Rotterdam-NL, Nantes-FR, Würzburg-DE, Melbourne-AUS, Sydney-AUS, Ankara-TR, Pessac-FR, Firenze-IT, Poitiers-FR, Pavia-IT, Toulouse-FR, Bologna-IT, Brescia-IT, Titusville NJ-US, Spring House PA-US, Pamplona-ES, Athens-GR, Turin-IT*)

**P13**

ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT: FINAL ANALYSIS OF A PHASE 2 STUDY BY GREEK MYELOMA STUDY GROUP

E. Terpos, E. Kastritis, S. Delimpasi, K. Papathanasiou, V. Labropoulou, N. Kanellias, I.N. Stathopoulos, M. Migkou, E. Solia, F. Theodorakakou, E.E. Papaikakou, M. Kotsopoulou, E. Katodritou, M. Gavriatopoulou, M.A. Dimopoulos (*Athens-GR, Ioannina-GR, Patras-GR, Piraeus-GR, Thessaloniki-GR, Seoul-KR*)

**P14**

DARATUMUMAB-BORTEZOMIB-MELPHALAN-PREDNISONE (DVMP) VS. DARATUMUMAB-LENALIDOMIDE-DEXAMETHASONE (DRD) IN TRANSPLANT-INELIGIBLE REAL-LIFE PATIENTS WITH MULTIPLE MYELOMA: A SUBANALYSIS OF THE PHASE IV REAL MM TRIAL

L. Cani, S. Bringhen, A. Piciocchi, N. Giuliani, S. Mangiacavalli, A.P. Falcone, G. Benevolo, M. Capriata, F. Vassallo, F. Ciceri, F. Pane, R. Floris, M. Cantonetti, S. Pezzatti, M. D'agostino, A. Casson, A. Evangelista, E. Saraci, M. Mirabile, B. Gamberi, A. Conconi, G. Pietrantuono, P. Galieni, P. Curci, G. Margiotta-Casaluci, A. Liso, M. Scaldaferrri, B. Bruno, M. Boccadoro, A. Larocca (*Torino-IT, Cuneo-IT, Rome-IT, Parma-IT, Pavia-IT, San Giovanni Rotondo-IT, Milano-IT, Naples-IT, Cagliari-IT, Monza-IT, Civitanova Marche-IT, Reggio Emilia-IT, Biella-IT, Rionero in Vulture-IT, Ascoli Piceno-IT, Bari-IT, Novara-IT, Perugia-IT, Terni-IT, EMN-IT*)

**P15**

RANDOMIZED COMPARISON OF ISATUXIMAB-RD INDUCTION FOLLOWED BY ISA R MAINTENANCE VERSUS RD INDUCTION FOLLOWED BY R MAINTENANCE IN ELDERLY PTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (AGMT MM04 TRIAL)

H. Ludwig, T. Melchardt, E. Terpos, J. Bila, M. Schreder, S. Bernhard, K. Podar, E. Katodritou, T. Sliwa, P. Djurdjevic, S. Delimpasi, M. Leisch, M. Mitrovic, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, E.M. Autzinger, A. Zabernigg, M. Fillitz, E. Wöll, P. Pichler, I.M. Sáenz De Tejada, B. Paiva, R. Greil (*Vienna-AT, Salzburg-AT, Athens-GR, Belgrade-SRB, Krems an der Donau-AT, Thessaloniki-GR, Leoben-AT, Kragujevac-SRB, Kufstein-AT, Zams-AT, St. Pölten-AT, Pamplona-ES*)

**P16**

INTEGRATED P53 ISOFORM EXPRESSION DEFINES NOVEL PROGNOSTIC SUBGROUPS IN MULTIPLE MYELOMA

E. Borsi, A. Vitale, V. Solli, V. Meixian Vuong, M. Martello, I. Vigliotta, S. Armuzzi, A. Poletti, B. Taurisano, A. Varacalli, G. Mazzocchetti, A. Croce, I. Pistis, E. Zamagni, P. Tacchetti, I. Rizzello, M. Cavo, C. Terragna (*Bologna-IT*)

**P17**

EARLY TREATMENT RESPONSE EVALUATION WITH WHOLE BODY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOCAL LESIONS

I. Ntanasis-Stathopoulos, V. Koutoulidis, M. Gavriatopoulou, M. Douka, P. Malandrakis, C. Filippatos, V. Spiliopoulou, F. Theodorakakou, I. Katsadourous, I. Solia, P. Boutsikos, M. Migkou, N. Kanellias, E. Eleutherakis-Papaikakou, E. Kastritis, L.A. Mouloupoulos, M.A. Dimopoulos, E. Terpos (*Athens-GR, Seoul-KR*)

**P18**

MONOCLONAL AND POLYCLONAL CIRCULATING PLASMA CELLS ARE ASSOCIATED WITH DISEASE DISSEMINATION IN MULTIPLE MYELOMA

I. Vigliotta, A. Varacalli, M. Talarico, V. Solli, B. Taurisano, S. Armuzzi, I. Pistis, V.M. Vuong, A. Vitale, G. Mazzocchetti, E. Borsi, A. Croce, M. Martello, A. Poletti, C. Nanni, K. Mancuso, M. Puppi, M. Cavo, E. Zamagni, C. Terragna (*Bologna-IT, Aosta-IT*)

**P19**

IMS-IMWG CONSENSUS GENOMIC STAGING IN NEWLY DIAGNOSED MULTIPLE MYELOMA USING THE UMA PANEL: A DAILY CLINICAL PRACTICE EXPERIENCE

B. Taurisano, V.M. Vuong, A. Poletti, S. Armuzzi, I. Vigliotta, A. Varacalli, I. Pistis, G. Mazzocchetti, M. Martello, A. Croce, E. Borsi, V. Solli, A. Vitale, K. Mancuso, I. Sacchetti, M. Cavo, N. Bolli, E. Zamagni, C. Terragna (*Bologna-IT, Aosta-IT, Milano-IT*)

**P20**

INFLAMMATION SCORE (I-SCORE) IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A NEW EASY TOOL TO ASSESS PROGNOSIS

V. Bongarzone, B. Anacletico, G. Tomei, S. Morè, F. Di Landro, F. Fazio, F. Fioritoni, G. Antolino, S. Gentili, L. De Padua, L. Cupelli, S. Gumenyuk, M. Di Cecca, M. Garzia, L. Fiori, A. Rago, P. Arcuri, E. Rossi, M. Capriata, M. Offidani, A. Andriani, R. Latagliata (*Rome-IT, Viterbo-IT, Ancona-IT, Pescara-IT, Macerata-IT, Frosinone-IT, Latina-IT*)

**P21**

THE LONG TERM PROGNOSTIC IMPACT OF CHROMOSOME 1 ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

N. Iannozzi, G. Sammarelli, G. Todaro, A. Poletti, M. Scita, B. Dalla Palma, M. Bernardi, C. Sitzia, N. Giuliani (Parma-IT)

**P22**

WHEN TRIAL DESIGN MEETS APPROVED MAINTENANCE: A SINGLE-CENTER REAL-WORLD EXPERIENCE WITH DARA-VTD INDUCTION AND CONSOLIDATION FOLLOWED BY LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA

A. Belotti, S. Terlizzi, S. Martorana, R. Ribolla, C. Crippa, S. Ferrari, N. Bianchetti, C. Bottelli, C. Cattaneo, M. Chiarini, V. Giustini, A. Roccaro, A. Tucci (Brescia-IT)

**P23**

DARA-VTD AND ASCT+ LENALIDOMIDE LED TO HIGH CR AND MRD NEGATIVITY RATES BY NGF: A REAL-WORLD STUDY OF THE TUSCAN MYELOMA NETWORK (RTM) IN 228 PATIENTS

V. Venanzi, S. Ciofini, E. Antonioni, G. Buda, E. Bestoso, D. Raspadori, V. Candi, L. Pengue, M.L. Del Giudice, A. Caremani, S. Moretti, G. Fontanelli, I. Attucci, M.T. Pirrotta, C. Biagiotti, S. Birtolo, S. Grammatico, S. Pileri, L. Notarfranchi, G. Tancredi, S. Galimberti, M. Bocchia, A. Gozzetti (Siena-IT, Firenze-IT, Pisa-IT, Arezzo-IT, Prato-IT, Pistoia-Pescia-IT, Empoli-IT, Lucca-IT, Massa Carrara-IT)

**P24**

APPROACHING CURE IN MULTIPLE MYELOMA: A DUAL-CENTER EXPERIENCE AMONG PATIENTS DIAGNOSED BEFORE 2010

G. Cengiz Seval, H. Aytekin, T. Otlu, U. Calis, M. Beksac (Ankara-TR)

**P25**

REAL-WORLD OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: EVIDENCE SUPPORTING BORTEZOMIB-LLENALIDOMIDE-DEXAMETHASONE AS A PREFERRED REGIMEN WITHOUT ANTI-CD38 ANTIBODIES

A. Jungova, M. Stork, I. Spicka, J. Radocha, J. Minarik, P. Pavlicek, J. Mihalyova, L. Pour, J. Straub, V. Maisnar, T. Pika, T. Dekojova, J. Soukup, T. Popkova, K. Mensikova, F. Sedlak, J. Pospiskova, I. Boichuk, P. Krhovska, T. Stopka, P. Jindra, T. Jelinek, Z. Knechtova, V. Capounova, V. Latal, L. Muronova, A. Heindorfer, J. Ullrychova, M. Sykora, P. Kessler, R. Hajek (Pilsen-CZ, Brno-CZ, Prague-CZ, Hradec Kralove-CZ, Olomouc-CZ, Ostrava-CZ, Liberec-CZ, Usti nad Labem-CZ, Ceske Budejovice-CZ, Pelhrimov-CZ)

**P26**

CORRELATION OF THE CIRCULATING TUMOR CELLS AND R2-ISS SCORE IN NEWLY DIAGNOSED MYELOMA PATIENTS: RWE EXPERIENCE

N. Kecman, M. Mitrovic, A. Sretenovic, Z. Bukumiric, I. Tanovic, N. Kraguljac Kurtovic, J. Jovanovic, J. Bila (Belgrade-RS)

**P27**

OPTIMIZATION OF MELPHALAN DOSAGE THROUGH ELIMINATION OF METABOLITES VIA HEMODIALYSIS IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT

C. Schaaf, J. Steinhaus, M. Högner, M. Verbeek, D. Czock, K. Kleigrew, F. Hackbarth, M. Braunisch, R. Günthner, J. Jung, S. Niedermayer, S. Röder, T. Langseder, J. Matschkal, J. Lecce, L. Platen, N. Hannane, L. Mertens, J. Carbajo-Lozoya, C. Fiorentini, S. Glowka, F. Keller, U. Heemann, C. Schmaderer, F. Bassermann, L. Renders, C. Küchle (Munich-DE, Heidelberg-DE, Freising-DE, Ulm-DE)

**P28**

ON DEMAND PLERIXAFOR FOR STEM CELL MOBILIZATION WITH G CSF ONLY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB: A SINGLE CENTER EXPERIENCE

B. Skopec, L. Cemazar, M. Skerget (Ljubljana-SVN)

**P29**

PLATELET AGGREGATION AND THROMBIN GENERATION IN MULTIPLE MYELOMA: A PROSPECTIVE STUDY

M. Biglietto, R. Mormile, A. Piciocchi, F. Fazio, M. Capriata, S. Sorella, B. Mandelli, D. Kasmi, E. Baldacci, A. Chistolini, M.T. Petrucci, C. Santoro (Rome-IT)

**P30**

PROGNOSTIC IMPACT OF THE LYMPHOCYTE-TO-ALBUMIN RATIO IN PATIENTS WITH MULTIPLE MYELOMA

G.A. Cagliyan (Denizli-TR)

**P31**

PROGNOSTIC IMPACT OF INTERPHASE FISH IN MULTIPLE MYELOMA: SINGLE-CENTER IRISH EXPERIENCE

T. Pramod, A. Bannaga, S. Kumar, B. Hennessy, E. El Hassadi (Waterford-IE)

**P32**

MULTIPLE MYELOMA PRESENTING AS ACUTE BACK PAIN AND KIDNEY INJURY: A DIAGNOSTIC CHALLENGE

M. Hammad, O. Elsega (Preston-UK, Manama-BH)

### 3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

#### P33

ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1-3 PRIOR REGIMENS

S. Bal, M. Htut, J. Berdeja, L. Anderson, A. Rossi, T. Gregory, L. Costa, H. Hu, Z. Guo, J. Chen, K. Jordahl, N. Sarkis, S. Ziyad, W.M. Kao, A. Kaeding, M. Burgess, O. Nadeem (Birmingham-USA, Duarte-USA, Nashville-USA, Dallas-USA, New York-USA, Denver-USA, Princeton-USA, Boston-USA)

#### P34

CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (POM-DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): BIOMARKER ANALYSES FROM CAMMA 1 ARM B

R. Popat, S. Harrison, C.H. Riley, H.S. Mian, A. Spencer, N. Lavi, L. Paris, T. Jelínek, M. Szarejko, S. Grosicki, K. Kim, I. Sandhu, S. Chebon, T. Tyagi, P. Sewpaul, L. Richardson, K. Trunzer, A. Mishra, S. Trudel (London-UK, Melbourne-AU, Copenhagen-DK, Hamilton-CA, Haifa-IL, Bergamo-IT, Ostrava-CZ, Gdansk-PL, Katowice-PL, Seoul-KR, Edmonton-CA, Basel-CH, South San Francisco-USA, Welwyn-UK, Toronto-CA)

#### P35

PROLONGED ELRANATAMAB TREATMENT INTERRUPTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MAGNETISMM-3 RETROSPECTIVE ANALYSIS

E. Searle, A. Lesokhin, R. Niesvizky, B. Arnulf, S. Larson, C. Strouse, C. Fernandez De Larrea, D. Vesole, Y. Nagai, S.T. Sullivan, E. Leip, N. Bahlis (Manchester-UK, New York-USA, Paris-FR, Santa Monica-USA, Iowa City-USA, Barcelona-ES, Hackensack-USA, Kobe-JP, Cambridge-USA, Calgary-CA)

#### P36

EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

E. Zamagni, B. Dhakal, S. Iida, M.H. Sidiqi, S. S. Yoon, N. Callander, C. Touzeau, Q. Li, A. Balogh, A. Slaughter, N. Benachour, C. Lonardi, A. Ghosh, M. Vogel, N. Lendvai, T. Lengil, M. Koneru, N. Patel, O. Costa Filho, V. Mahajan, J. Martínez-López, K. Yong, K. Weisel, X. Leleu (Bologna-IT, Milwaukee-USA, Nagoya-JP, Perth-AUS, Seoul-KR, Madison-USA, Nantes-FR, Apex-USA, Beerse-BE, Zug-CH, Buenos Aires-AR, Raritan-USA, Neuss-DE, Somerset-USA, Madrid-ES, London-UK, Hamburg-DE, Poitiers-FR)

#### P37

ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALITAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS

R. Popat, K.M. Kortüm, H. Magen, V. Mykytiv, C. Liberatore, E. Zamagni, M.C. Da Vià, E. Antonioli, M. Hansson, D. Santra, D. Greer, K. Subrt, P. Hu, E. Aeby, N. Francella, N.M. Suñe, A. Perrot, K. Uttervall (London-UK, Würzburg-DE, Tel Aviv-IL, Cork-IE, Pescara-IT, Bologna-IT, Milan-IT, Florence-IT, Gothenburg-SE, Sheffield-UK, Raleigh-USA, Prague-CZ, Raritan-USA, Zug-CH, Beerse-BE, Madrid-ES, Toulouse-FR, Stockholm-SE)

#### P38

SAFETY AND EFFICACY OF TALQUETAMAB (TAL) + TECLISTAMAB (TEC) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) FROM PHASE 1B OF REDIRECTT-1: RESULTS WITH AN EXTENDED MEDIAN FOLLOW-UP OF 3 YEARS

E.M. Ocio, M.V. Mateos, H. Magen, M. Gatt, M. Sebag, K. Kim, C.K. Min, S.S. Yoon, M.P. Chu, P. Rodríguez-Otero, I. Avivi, N.A. Quijano Cardé, M. Krevvata, T. Henninger, P. Thakkar, M. Festa, L. Huang, J. Zhou, M. Takamoto, L. Pei, J. Lu, C. Maffucci, E. Scott, A. Oriol, D. Morillo, Y.C. Cohen (Santander-ES, Salamanca-ES, Tel Aviv-IL, Jerusalem-IL, Montreal-CA, Seoul-KR, Edmonton-CA, Pamplona-ES, Spring House-USA, Raritan-USA, Leiden-NL, Tokyo-JP, Shanghai-CN, Badalona-ES, Madrid-ES)

#### P39

RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

E. Searle, V. Campbell, C. Pawlyn, D. Vogl, S. Holstein, S. Gooding, M. Jenner, T. Creasey, A. Chaidos, P. Rodríguez-Otero, F. Al-Kaisi, Brearton, S. Moore, J. O'nions, T. Somerville, T. Knurowski, K. Clegg, S. Paul, K. Frese, N. Joseph (Manchester-UK, Edinburgh-UK, London-UK, Philadelphia-USA, Omaha-USA, Oxford-UK, Southampton-UK, Newcastle upon Tyne-UK, Pamplona-ES, Derby-UK, Liverpool-UK, Cambridge-UK, Atlanta-USA)

#### P40

EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE REDIRECTT-1 STUDY WITH EXTENDED FOLLOW-UP

M. Mateos, P. Rodríguez-Otero, S.Z. Usmani, S. Kumar, J.C. Ye, S. Atrash, H. Magen, H. Quach, M.P. Chu, S. Trudel, J. Richter, H. Chuah, M. Gatt, E. Medvedova, S. Raza, D.H. Yoon, T. Ishida, J.V. Matous, L. Rosinol, K. Onodera, C. Maffucci, E. Scott, C. Heuck, J. Zhang, T. Henninger, L. Orourke, P. Thakkar, M. Festa, L. Huang, J. Zhou, M. Takamoto, L. Pei, J. Lu, N. Au, M. Krevvata, Y.C. Cohen (Salamanca-ES, Pamplona-ES, New York-USA, Rochester-USA, Houston-USA, Charlotte-USA, Tel Aviv-IL, Melbourne-AUS, Edmonton-CA, Toronto-CA, Perth-AUS, Jerusalem-IL, Portland-USA; Cleveland-USA, Seoul-KR, Tokyo-JP; Denver USA, Barcelona-ES, Sendai-JP, Raritan-USA; Spring House-USA, Leiden-NL, Shanghai-CN)

**P41**

FIRST RESULTS OF REALITEC-2: SECOND COHORT OF REALITEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE

R. Popat, K. Uttervall, K.M. Kortum, H. Magen, M. Hansson, T. Shragai, E. Terpos, C.T. Hansen, S. Manier, H. Gregersen, O.M. Ottestad, C. Touzeau, E. Hatjiharissi, S.L. Farmer, E. Katodritou, E. Spanoudakis, M.O. Vase, C. Liberatore, M. Papatthaniou, M.K. Angelopoulou, E. Clavero, R. Kittus, P. Smirnov, P. Hu, D. Santra, C. Albrecht, E. Rubio-Azpeitia, A. Perrot (London-UK, Stockholm-SE, Wurzburg-DE, Tel-Aviv-IL, Gothenburg-SE, Athens-GR, Odense-DK, Lille-FR, Aalborg-DK, Lorenskog-NO, Nantes-FR, Thessaloniki-GR, Vejle-DK, Alexandroupolis-GR, Aarhus-DK, Pescara-IT, Chieti-IT, Granada-ES, Milan-IT, Raritan, NJ-USA, Sheffield-UK, Issy les Moulineaux-FR, Madrid-ES, Toulouse-FR)

**P42**

COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALITEC VS REAL-WORLD PHYSICIAN'S CHOICE OF THERAPY IN LOCOMOTION AND MOMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA

A.A. Perrot, M. Kortum, R. Popat, K. Uttervall, M.V. Mateos, K. Weisel, K. Van Nimwegen, J. Diels, F. Ong, R. Morano, E. Rubio-Azpeitia, P. Moreau (Toulouse-FR, Wurzburg-DE, London-UK, Stockholm-SE, Salamanca-ES, Hamburg-DE, Breda-NL, Beerse-BE, Raritan, NJ-US; Madrid-ES, Nantes-FR)

**P43**

SELINEXOR, MEZIGDOMIDE, AND DEXAMETHASONE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RELAPSED OR ARE INELIGIBLE FOR T-CELL-REDIRECTING THERAPY (TCRT): STOMP PHASE 1 PRELIMINARY RESULTS

C. Mo, C. Gasparetto, C. Costa, A.J. Cowan, T. Mark, Y. Chai, T. Kashyap, J. Katz, M. Amatangelo, P.G. Richardson (Boston-USA, Durham-USA, Seattle-USA, Newton-USA, Princeton-USA)

**P44**

EARLIER USE OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IS ASSOCIATED WITH BETTER IMMUNE FITNESS AND STRONGER IMMUNE EFFECTS AS SHOWN BY CORRELATIVE ANALYSIS OF PERIPHERAL BLOOD AND THE BONE MARROW TUMOR MICROENVIRONMENT (TME) FROM THE CARTITUDE-4 STUDY

N.W.C.J. Van De Donk, S. Parekh, K. Li, Y. Lin, T.G. Martin, S. Han, R. Montes De Oca, M. Suraneni, M. Gormley, B. Hodgkinson, J. Yuan, F. Wang, A. Kumar, D. Yin, D. Smirnov, J. Patel, N. Lendvai, D. Madduri, J. Zhu, M. Koneru, N. Patel, D. Geng, V. Plaks, S. Harrison (Amsterdam-NL, New York-USA, Spring House-USA, Rochester-USA, San Francisco-USA, San Diego-USA, Shanghai-CN, Raritan-USA, Somerset-USA, Melbourne-AUS, Parkville-AUS)

**P45**

MODELING DORMANCY IN MULTIPLE MYELOMA: FUNCTIONAL AND TRANSCRIPTOMIC CHARACTERIZATION OF SERUM STARVATION AND CHEMOTHERAPY-INDUCED STATES

Z.S. Najafabadi, N. Afrin, M. Helal, H. Fischer, M. John, E. Stanojkowska, J. Mersi, S. Kadel, J. Waldschmidt, M. Kortum, K. Kretzschmar, H. Einsele, A. Riedel, L. Rasche (Würzburg-DE)

**P46**

CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY

I. Vigliotta, A. Varacalli, M. Talarico, M. Puppi, S. Armuzzi, B. Taurisano, I. Pistis, V. Solli, V.M. Vuong, E. Borsi, A. Vitale, G. Mazzocchetti, A. Croce, M. Martello, A. Poletti, M. Cavo, E. Manzato, E. Zamagni, C. Terragna (Bologna-IT, Aosta-IT)

**P47**

UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY

R. Popat, N.W.C.J. Van De Donk, B. Faiman, J. Yuda, K. Kim, A. Costa, A. Laheij, R.L. Doty, J. Omel, B. Lipe, L. Sanchez, A. Chari, A. Lin, H. Sroussi, M. Fernandez, K.S. Gray, G. Aguilar, K. Bolyard, J. Schultz, K. Qi, D. Cortes-Selva, J. Zhang, C. Heuck, K. Hawks, K. Tian, M. França, L. Rasche (London-UK, Amsterdam-NL, Cleveland-USA, Kashiwa-JP, Seoul-KR, São Paulo-BR, Philadelphia-USA, Grand Island-USA, Rochester-USA, New York-USA, San Francisco-USA, Boston-USA, Madrid-ES, Bridgewater-USA, Leiden-NL, Raritan, NJ-US, Titusville, NJ-US, Spring House-USA, La Jolla-USA, Würzburg-DE)

**P48**

LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA

D. Dytfeld, L.J. Costa, A. Oriol, S. Manier, P.M. Voorhees, Y. Lin, M. Htut, W. Roeloffzen, P.J. Ho, U. Shah, M. Zhao, Q. Li, A. Balogh, K. Li, A. Slaughter, N. Benachour, C. Lonardi, A. Ghosh, H. Sun, N. Lendvai, T. Lengil, N. Patel, M. Koneru, E. Florendo, O. Costa Filho, V. Mahajan, P. Rodríguez-Otero, C. Strouse, A.K. Stewart, S. Sidana (Poznań-PL, Birmingham-USA, Barcelona-ES, Lille-FR, Charlotte-USA, Rochester-USA, Duarte-USA, Groningen-NL, Sydney-AU, New York, NY-US, Shanghai-CN, Apex, NC-US, Beerse-BE, Spring House-USA, Zug-CH, Buenos Aires-AR, Raritan-USA, Somerset-USA, Pamplona-ES, Iowa City-USA, Toronto-CA, Stanford-USA)

**P49**

IMPACT OF CYTOMEGALOVIRUS SEROSTATUS ON RESPONSE AND TREATMENT OUTCOMES WITH CD38 MONOCLONAL ANTIBODIES IN MULTIPLE MYELOMA PATIENTS

M. Garibotto, A. Gambino, V. Fontana, M. Olivieri, E. Tedone, A. Parodi, R. Mangerini, N. Colombo, S. Rosellini, D. Soncini, G. Giorgetti, I. Traverso, F. Guolo, A. Cagnetta, R.M. Lemoli, M. Cea (Genoa-IT)

**P50**

INPATIENT VS OUTPATIENT TREATMENT MANAGEMENT WITH TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A COST AND HEALTHCARE RESOURCE UTILISATION ANALYSIS

N. Van De Donk, R. Wester, I. Nijhof, C. Albrecht, R. Morano, C. Entrala, K. Van Nimwegen (Amsterdam-NL, Rotterdam-NL, Nieuwegein-NL, Paris-FR, Madrid-ES, Breda-NL)

**P51**

EVOLVING ATTRITION RATES IN MM REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE

G. Giunta, C. Bellofiore, E. Scalisi, F. Elia, B. Garibaldi, C. Finocchiaro, F. Di Raimondo, A. Romano, C. Conticello (Catania-IT)

**P52**

CILTACABTAGENE AUTOLEUCEL OUT-OF-SPECIFICATION MANUFACTURING OUTCOMES IMPROVE WITH EARLIER LINES OF THERAPY

R. Bowden, H. Van Eeckhoutte, G. Chow, G. Choudhary, L. Kallenbach, V. Alegria, M. Perciavalle, J. Salmon, J. Kang, M. Mondon, J. Vanak, D. Ciccone, P. Millili, M. Onorata, V. Plaks, M. Merz (Spring House-USA, New Brunswick-USA, Titusville-USA, Horsham-USA, Somerset-USA, New York-USA)

**P53**

NATIONWIDE EXPERIENCE WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL WORLD STUDY ON BEHALF OF THE GRUPPO ITALIANO MALATTIE EMOLOGICHE DELL'ADULTO FOUNDATION

M. Puppi, M. Pennisi, F. Monaco, L. Paris, S. Aquino, F. Ciceri, M. C. Goldaniga, M. Musso, G. Buda, M. Martino, P. Chiusolo, F. Fazio, R. Mina, F. Patriarca, M.C. Tisi, P. Tacchetti, V. Marasco, F. Ardizzoia, M. Talarico, K. Mancuso, E. Maffini, C. Carniti, C. Terragna, E. Zamagni, F. Bonifazi, M. Cavo, P. Corradini (Bologna-IT, Milano-IT, Alessandria-IT, Bergamo-IT, Genova-IT, Palermo-IT, Pisa-IT, Reggio Calabria-IT, Roma-IT, Torino-IT, Udine-IT, Vicenza-IT)

**P54**

EVOLVING OUTCOMES IN MM REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE

G. Giunta, C. Bellofiore, E. Scalisi, V. Del Fabro, F. Elia, B. Garibaldi, C. Finocchiaro, F. Di Raimondo, A. Romano, C. Conticello (Catania-IT, Enna-IT)

**P55**

MANAGEMENT OF NEUROLOGICAL TOXICITIES OF PATIENTS TREATED WITH IMMUNOTHERAPIES FOR MULTIPLE MYELOMA: A SINGLE-CENTRE REAL WORLD EXPERIENCE

E. Manzato, M. Puppi, M. Talarico, M. Iezza, S. Masci, S. Ghibellini, A. Vitale, S. Barbato, P. Tacchetti, L. Pantani, K. Mancuso, E. Zamagni (Bologna-IT)

**P56**

BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS.

R. Della Pepa, A. Leone, L. Esposito, G.L. D'Elia, V. Cerbone, M. Raia, G. Scalia, F. Pane (Napoli-IT)

**P57**

MELFLUFEN IS EFFECTIVE AND SAFE IN MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT

C. Bellofiore, V. Del Fabro, C. Finocchiaro, F. Elia, D. Leotta, B. Garibaldi, A. Petronaci, F. Di Raimondo, A. Romano, C. Conticello (Catania-IT, Enna-IT)

**P58**

TRIAL IN PROGRESS: QUINTESSENTIAL-2—A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) EXPOSED TO LENALIDOMIDE

E. Lebel, A. Abdulgawad, S. Bramanti, G. Garate, P.J. Ho, M. Keränen, Y. Cohen, M. Vase, A. Khot, I. Kristensen, R. Leblanc, C. Lee, W. Legiec, H. Magen, M.V. Mateos, D. Oh, L. Pour, N. Schutz, A. Spyridonidis, K. Weisel, J. Zaucha, S. Larson, A. Varshavsky-Yanovsky, K. Grazioli, D. Basudhar, H. Hu, Y. Meng, L. Eldjerou, S. Bal, S. Harrison, R. Popat, M. Raab, P. Rodriguez-Otero (Jerusalem-IL, Manchester-UK, Rozzano-IT, Buenos Aires-AR, Camperdown-AU, Helsinki-FI, Tel Aviv-IL, Midtjylland-DK, Victoria-AU, Syddanmark-DK, Quebec-CA, Adelaide-AU, Lublin-PL, Tel-Aviv-IL, Salamanca-ES, Victoria-AU, Brno-CZ, Buenos Aires-AR, Rio-Patras-GR, Hamburg-DE, Gdansk-PL, Los Angeles-US, Philadelphia-US, Princeton-US, Birmingham-US, London-UK, Heidelberg-DE, Pamplona-ES)

**P59**

BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES

D. Stoumbos, A. Antoniou, K. Lampropoulos, S. Chrysoglou, C. Prifti, M. Panagiotouni, M. Dadakaridou, S. Giourgouli, K. Stefanidis, M. Kotsopoulou (Athens-GR)

**P60**

TRIAL IN PROGRESS, MOMMENT-3: A PROSPECTIVE, MULTINATIONAL, REAL-WORLD STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

K. Weisel, E. Kastiris, E. Gonzalez-Garcia, S. Gentili, C. Renner, P. Ferraz, N. Francella, S. Sitar, J. Buyze, N. Healy, N. Martin Suñe, M.V. Mateos (Hamburg-DE, Athens-GR, Gijón-ES, Civitanova Marche-IT, Zurich-CH, Vila Real-PT, Beerse-BE, Toronto-CA, Dublin-IE, Madrid-ES, Nantes-FR, Salamanca-ES)

**P61**

IMMUNE EFFECTOR CELL COLITIS DURING TREATMENT WITH AN ANTI BCMA BISPECIFIC ANTIBODY

M. Minnema, H. Fidder, R. Oostvogels, V. Biemans (Utrecht-NL)

**P62**

INITIAL EXPERIENCE WITH IDECABTAGENE VICLEUCEL (ABECMA) IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA: CASE SERIES IN A TERTIARY CARE HOSPITAL

L. Piquer Monsonis, A. Pérez Montaña, J. Sánchez Raga, A. Sampol Mayol, M. Galí Sampol, R. Ferrero Guillén, E. Serrasoles Alemany, M. Remezal Serrano, A. Alonso Carballo, S. Montolio Chiva, P. Gómez Fernández, J. Domínguez Esteve, A. Horrillo Orejudo (*Palma de Mallorca-ES, Inca-ES*)

**4. SPECIAL CONDITIONS**

**P63**

TECLISTAMY (EMN40): A PHASE 2 TRIAL OF TECLISTAMAB (TEC) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED LIGHT-CHAIN (AL) AMYLOIDOSIS

M. Roussel, E. Kastritis, S. Schönland, K. Kortüm, B. Arnulf, A. Jaccard, S. Vara, M. Doyle, J. Schechter, A. Carpinteiro, F. Kwok, G. Palladini, M. Minnema, M. Boccadoro, P. Sonneveld (*Limoges-FR, Athens-GR, Heidelberg-DE, Würzburg-DE, Paris-FR, Wycombe-UK, Dublin-IE, Raritan-USA, Essen-DE, Sydney-AUS, Pavia-IT, Utrecht-NL, EMN-IT, Rotterdam-NL, EMN-NL*)

**P64**

ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE

N. Sgherza, E. Antonioli, E. Zamagni, C. Conticello, F. Fazio, S. Palmieri, A. Cagnetta, G. Palumbo, A. Solimando, R. Della Pepa, C. Germano, G. Palazzo, C. De Risi, A. Quinto, G. Buda, M. Gentile, O. Annibali, D. De Novellis, P. Curci, O. Battisti, L. Pavan, M. Capriata, G. Di Carlo, G. Proietti, V. Del Fabro, A. Falcone, R. Spadano, D. Derudas, G. Mele, G. Barilà, M. Petrucci, F. Di Raimondo, F. Albano, P. Musto (*Bari-IT, Firenze-IT, Bologna-IT, Catania-IT, Roma-IT, Napoli-IT, Genova-IT, Foggia-IT, Barletta-IT, Taranto-IT, Lecce-IT, Pisa-IT, Cosenza-IT, Salerno-IT, Padova-IT, Enna-IT, San Giovanni Rotondo-IT, Pescara-IT, Cagliari-IT, Brindisi-IT, Vicenza-IT*)

**P65**

FUNCTIONAL HIGH RISK MULTIPLE MYELOMA IN THE ANTI CD38 QUADRUPLET ERA: REDEFINITION THROUGH REAL WORLD DATA

S. Morè, M. Offdani, L. Corvatta, T. Za, F. Fazio, M. Gherardini, V. Bongarzone, B. Anaclerico, L. Franceschini, S. Ferraro, L. Cupelli, R. Spadano, L. De Padua, A. Rago, S. Gentili, R. Latagliata, M. Garzia, I. Cordone, V. Mezzanotte, E. Rossi, F. Di Landro, Z. Limongi, E. Morsia, A. Poloni, M. Petrucci (*Ancona-IT, Fabriano-IT, Rome-IT, Pescara-IT, Frosinone-IT, Civitanova Marche-IT, Viterbo-IT*)

**P66**

VALIDATION OF NOVEL PROGNOSTIC MODELS IN SYMPTOMATIC WALDENSTRÖM'S MACROGLOBULINEMIA BASED ON REAL-WORLD DATA

M. Kascak, P. Vodicka, K. Mensikova, M. Stork, Z. Adam, D. Salek, A. Janikova, J. Karban, J. Salkova, M. Spacek, D. Belada, A. Sykrova, M. Simkovic, P. Stepankova, J. Radocha, A. Jungova, T. Dekojova, P. Jindra, K. Steinerova, T. Prochazka, T. Jelinek, D. Žihala, J. Ďuraš, V. Prochazka, A. Obr, V. Hanackova, J. Minarik, A. Heindorfer, J. Klcova, H. Mocikova, J. Soukup, M. Sykora, P. Kessler, R. Schulzova, M. Wrobel, L. Stejskal, P. Mikula, V. Campr, J. Dlouha, P. Blahovcova, I. Kovacova, L. Pour, M. Trneny, R. Hajek (*Ostrava-CZ, Prague-CZ, Brno-CZ, Hradec Kralove-CZ, Pilsen-CZ, Olomouc-CZ, Liberec-CZ, Ceske Budejovice-CZ, Pelhrimov-CZ, Mlada Boleslav-CZ, Novy Jicin-CZ, Opava-CZ, Havirov-CZ*)

**P67**

TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS

T. Shragai, M. Ganayem, Y. Cohen, I. Avivi, E. Lebel, N. Even-Gross Zohar, N. Melamed, M. Gatt (*Tel-Aviv-IL, Jerusalem-IL*)

**P68**

BIOPSY SPECIFIC CHARACTERISTICS ARE IMPORTANT IN DETECTING AMYLOID IN PATIENTS WITH AMYLOIDOSIS

F. Weverling, A. Vinkenborg, R. Leguit, M. Minnema (*Utrecht-NL*)

**P69**

REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY: AN INTERIM ANALYSIS

E. Kastritis, S. Sánchez-Ramón, A. Szabo, B. Machalinski, A. Pérez-Montaña, J. Chen, B. Mc Coy, M. Kamieniak, S. Wietek (*Athens-GR, Madrid-ES, Copenhagen-DK, Szczecin-PL, Palma de Mallorca-ES, Cambridge-US, Vienna-AU*)

**P70**

NOVEL MGUS CARE PATHWAY FOR THE EARLY DETECTION OF M PROTEIN RELATED DISEASES

M. Minnema, F. Verheij, J. Kortleve, K. Aarsman, R. Blommers, R. Oostvogels, P. Westerweel (*Utrecht-NL, Dordrecht-NL*)

**P71**

DARATUMUMAB IN PATIENTS WITH AL AMYLOIDOSIS (DAR.AL): A PORTUGUESE MULTICENTER REAL-WORLD STUDY

R. Bergantim, A. Roque, J. Vieira, G. Ferreira, P. Martins Almeida, P. Ferraz, J. Guilherme Freitas, M. Neves, E. Aguiar, M. Lopes, H. Martins, F. Trigo, C. Gerales, C. João (*Porto-PT, Coimbra-PT, Lisboa-PT, Aveiro-PT, Vila Real-PT, Braga-PT, Santa Maria da Feira-PT*)

**P72**

BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS: CLINICAL EXPERIENCE IN 2 ACADEMIC BELGIAN CENTERS

M. Vekemans, O. Rizzo, N. Meuleman (*Brussels-BE*)

**P73**

TP53 MUTATION AND MSS-WM IDENTIFY HIGH RISK WALDENSTROM MACROGLOBULINEMIA IN A REAL WORLD COHORT

U. Calis, S. Yuksel, M. Kurt Yuksel, P. Topcuoglu, I. Kuzu, O. Arslan, M. Ozcan, T. Demirer, S. Kocak Toprak, M. Beksac, G. Cengiz Seval (*Ankara-TR*)

**P74**

AUTOMATED PANEL-AGNOSTIC FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA USING QUALITY CONTROL-AWARE MACHINE LEARNING

E. Akar, M. Baysal, S. Cakmak, S. Akpinar, B. Turgut (*Tekirdag-TR*)

**P75**

CURRENT STATUS OF REGISTRY OF MONOCLONAL GAMMOPATHIES (RMG) - THE CZECH MYELOMA GROUP "REAL WORLD" DATABASE

V. Maisnar, L. Pour, I. Spicka, J. Minarik, T. Jelinek, A. Jungova, P. Pavlicek, L. Roziakova, J. Radocha, A. Heindorfer, M. Sykora, P. Kessler, L. Stejskal, M. Wrobel, J. Kopeckova, K. Stankova, L. Pospisilova, R. Hajek (*Hradec Kralove-CZ, Brno-CZ, Prague-CZ, Olomouc-CZ, Ostrava-CZ, Plzen-CZ, Bratislava-SK, Liberec-CZ, Ceske Budejovice-CZ, Pelhrimov-CZ, Opava-CZ, Novy Jicin-CZ*)

**P76**

DIFFERENT OUTCOMES OF T(11;14) MULTIPLE MYELOMA AND THERAPY-RELATED ACUTE UNDIFFERENTIATED LEUKEMIA TO VENETOCLAX-BASED THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION

V. Latal, A. Kuba, T. Pika, M. Novak, J. Balcarkova, J. Navratilova, M. Cernan, T. Szotkowski, J. Minarik, T. Papajik (*Olomouc-CZ*)

**P77**

LIGHT CHAIN DEPOSITION DISEASE: A RARE CAUSE OF RENAL INJURY WITH EMERGING THERAPEUTIC OPTIONS

R. Cassano, S. Galimberti, A.G. Bonadio, L.M.A. Melillo, D. Giannese, G. Buda (*Foggia-IT, Seattle-USA, Pisa-IT*)

## ACKNOWLEDGEMENTS

With an unrestricted educational grant of

### PLATINUM SPONSOR



Johnson & Johnson

---

### GOLD SPONSOR



---

### SILVER SPONSOR



Stemline  
A Menarini Group Company



---

### CONTRIBUTORS

EMMES

HEALTH DATA SPECIALIST IRELAND

PAREXEL

SANOFI

SEBIA

TAKEDA

# 7<sup>th</sup> European Myeloma Network Meeting



## MEETING VENUE

### Clarion Congress Hotel Prague

Freyova 945/33,  
190 00 Praha 9-Vysočany, Cechia  
Ph +420 211 131 139  
[www.clarioncongresshotelprague.com](http://www.clarioncongresshotelprague.com)

## LOCAL ORGANIZERS

Roman Hajek (*Czech Republic*)  
Jakub Radocha (*Czech Republic*)

## PROGRAM COORDINATORS

Roman Hajek (*Czech Republic*)  
Jakub Radocha (*Czech Republic*)  
Niels van de Donk (*The Netherlands*)  
Francesca Gay (*Italy*)  
Elias Mai (*Germany*)  
Paula Rodriguez-Otero (*Spain*)

## EMN EXECUTIVES

EMN President  
Pieter Sonneveld (*The Netherlands*)  
EMN Vice President  
Mario Boccadoro (*Italy*)

## ORGANIZING SECRETARIAT

Studio E.R. Congressi  
Via De' Poeti 1/7 - 40124 Bologna, Italy  
Ph +39 051 4210559  
E-mail: [emnmeeting@ercongressi.it](mailto:emnmeeting@ercongressi.it)  
[www.ercongressi.it](http://www.ercongressi.it)

ER Congressi



Prague

April 16-18, 2026

Clarion Congress Hotel Prague